melanoma Archives | Oncotarget.net

Oncotarget News

Protein Linked to Melanoma Growth May Suppress the Body’s Natural Anti-Tumor Immune Response

June 17, 2026

However, DHHC3 does control primary melanoma growth by supporting anti-melanoma immunity.”BUFFALO, NY - June 17, 2026 – A new research paper was published in Volume 17 of Oncotarget on June 8,... read more

Oncotarget

The SCD1 Inhibitor Aramchol, Regorafenib, and Metformin Combine to Kill Uveal Melanoma Cells

March 31, 2026

Aramchol and metformin interacted to modestly enhance cell death in PDX UM cells, though this was less than that caused by the combination of aramchol and the multi-kinase inhibitor regorafenib.”... read more

Oncotarget

Protein GSK3β Offers New Angle on Overcoming Melanoma Drug Resistance

April 11, 2025

Inhibitors of GSK3β reduce the cell viability of BRAFi-resistant melanoma cell lines and thus may holds promise as a novel strategy to overcome BRAFi resistance and melanoma progression.”BUFFALO, NY -... read more

Chemical complementarity of tumor resident, T-cell receptor CDR3s and renalase-1 correlates with increased melanoma survival

Oncotarget

TCR CDR3s and Renalase-1 Linked to Increased Melanoma Survival

August 8, 2024

These findings indicate that renalase-1 is a potential antigen for TCR recognition in melanoma and could be considered as a target for immunotherapy.”BUFFALO, NY- August 8, 2024 – A new... read more

Oncotarget

Prognostic and Therapeutic Insights Into MIF, DDT, and CD74 in Melanoma

July 26, 2024

we present the first study to retrospectively evaluate differential gene expression of MIF, DDT, and relevant pathway markers in regard to clinical outcomes in patients with melanoma.”BUFFALO, NY- July... read more

Oncotarget

When Does a Melanoma Metastasize? Implications for Management

June 18, 2024

immunotherapy is more likely to be effective at eliminating metastatic disease if the tumor burden is low, making it more logical to treat patients with high-risk melanomas at the earliest... read more

Table 8: Control data for transfection efficiency of uveal melanoma cells

Oncotarget

GZ17-6.02 Kills PDX Isolates of Uveal Melanoma

May 22, 2024

The present studies demonstrated that GZ17-6.02 interacted with irreversible inhibitors of the EGF receptor and HER2 to kill uveal melanoma cells.”BUFFALO, NY- May 22, 2024 – A new research... read more

Oncotarget

A Macrophage is a Macrophage is a Macrophage—in Metastasis

August 23, 2023

We hope that these results will inform future attempts at anti-macrophage therapy and lead to better outcomes for patients in the not-too-distant future.” BUFFALO, NY- August 23, 2023 – A... read more

Figure 1: Combined targeting of SMO and BRD4 as a potential therapeutic strategy against melanoma.

Oncotarget

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

July 19, 2023

This evidence strengthens the relevance of the findings by Pietrobono et al., shedding light on the potential application of SMO inhibitors in concert with BRD4 inhibitors.”BUFFALO, NY- July 19,... read more

Figure 1: MALAT1-ASO specifically targets MALAT1-lncRNAs.

Oncotarget

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

May 30, 2023

In this study, we present novel transcriptional dependencies between MALAT1 and MAPK-pathway-associated genes in melanoma.”BUFFALO, NY- May 30, 2023 – A new research paper was published in Oncotarget's Volume 14... read more